Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06610539 · ClinicalTrials.gov registry record
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
A clinical trial of Breast Cancer, sponsored by Endomagnetics.
- Recruiting
- Registry status
- 184
- Enrollment target
- 2
- Study locations
NCT06610539: Recruiting study of Breast Cancer, sponsored by Endomagnetics.
NCT06610539 is a study of Breast Cancer that is actively recruiting participants, run by Endomagnetics. The registered enrollment target is 184 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06610539, a study of Breast Cancer, is actively recruiting participants, sponsored by Endomagnetics.
- RECRUITING
- Registry status
- 184 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on patients when it does occur using patient reported outcome measures.
Primary Outcome
Frequency of Magtrace-related skin discoloration as a proportion of patients receiving Magtrace, overall and by sub-sample
Conditions Studied
Study Locations (2)
North Carolina
- UNC, Lineberger Comprehensive Cancer Center - Chapel Hill
Virginia
- VCU Massey Comprehensive Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2025-04-22 |
| Est. Completion | 2028-11 |
What NCT06610539 shows while recruiting
NCT06610539 is an observational study that tracks outcomes without assigning an intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06610539 reports a single indexed study location in North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT06610539 about?
NCT06610539 is a clinical study titled "PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients". The purpose of this study is to provide prospective evidence in the US population of the frequency of skin discoloration and Sentinel Lymph Node detection rate in patients who have recevied Magtrace for Sentinel Lymph Node Biopsy (SLNB) and to evaluate the impact that skin discoloration has on patie...
What is the current status of trial NCT06610539?
This trial is currently recruiting. The enrollment target is 184 participants. The study started on 2025-04-22. Estimated completion is 2028-11.
What conditions does trial NCT06610539 study?
This clinical trial studies the following conditions: Breast Cancer.
Who is sponsoring clinical trial NCT06610539?
This trial is sponsored by Endomagnetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06610539 being conducted?
This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06610539's enrollment target sits among peer trials
184 400th of 1224 higher than 824 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI